Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
CY

Cytokinetics, Incorporated (CYTK)

NASDAQ • Healthcare

$65.91
+$0.26 (+0.4%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$65.9
Day Range$65.25 - $66.92
Avg. Volume (3M)2M
Market Cap$8.2B
52 Week Range
$54.3$88.31
Next EarningsIn 34 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$31.9M100%
Gross Profitminus cost of goods$29.1M91%

Fundamentals & Financials

Revenue (TTM)
$70.9M
Net Income (TTM)
-$894M
EPS (TTM)
-$7.21
ROA (TTM)
-46.45%
Current Ratio
6.66
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-1.4%Q1 2026-$1.5
0.0%Q2 2026-$1.67
+8.0%Q3 2026-$1.5
Next

Nov 4

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +8.0%

Cytokinetics topped EPS expectations while revenue fell year over year in the second fiscal quarter of 2026, reported August 6, 2026. EPS came in at -$1.50 versus the -$1.63 estimate (+8.0%), down from -$1.12 a year ago, as revenue declined 52.2% to roughly $31.9 million (from $66.8 million a year ago). Despite the lower top line, gross profit was about $29.2 million and gross margin held near 91%. Operating income was a loss of roughly $175.9 million, and the company posted a net loss of about $198.8 million, with net income down 47.9% year over year from a loss of $134.4 million. Consensus for the next period calls for EPS of -$1.45.

View full earnings history

About Cytokinetics, Incorporated

Cytokinetics, Incorporated is a NASDAQ-listed biotechnology company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors for cardiac and skeletal muscle diseases. Its business is centered in the United States, and it generated $88.0 million in revenue in FY2025.

Name
Cytokinetics, Incorporated
CEO
Robert I. Blum
Website
www.cytokinetics.com
Industry
Healthcare
Year Founded
1997
Employees
673

Today's Snapshot

AI-generated

CYTK ended the day slightly higher at 65.91, while its sector was weaker. Cytokinetics launched a real-world study of MYQORZO, a heart drug, in people with thickened heart muscle.

Trading Volume

Above 10d avg 2.4M

2.9M

vs S&P 500 Today

Moderate Outperformance

+0.22%

Updated: September 30, 2026 at 20:18 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
Cytokinetics presents a bearish technical profile with price trading below short-, medium- and long-term moving averages and sitting near the pivot level, while momentum measures are negative and MACD is notably below zero. RSI and CCI are toward the lower end of their ranges and on-balance volume is weak, suggesting distribution rather than accumulation, while ADX indicates only modest trend strength and ATR shows restrained volatility. Technical takeaway: Strong Sell — negative momentum and a price below major averages signal dominant selling pressure.
All signals
  • EMA (5 indicators)$66.99 - $73.17
    Sell
  • RSI (14)34.11
    Neutral
  • Stochastic %K (14, 3, 3)14.09
    Buy
  • MACD Level (12, 26)-2.67
    Sell

Peers & Related Assets

JAZZJazz Pharmaceuticals plc
$231.52-0.4%
HALOHalozyme Therapeutics, Inc.
$110.4-1.0%
CORTCorcept Therapeutics Incorporated
$115.23+0.4%
AXSMAxsome Therapeutics, Inc.
$184.39-0.9%
NUVLNuvalent, Inc.
$123.960.0%
RYTMRhythm Pharmaceuticals, Inc.
$95.22-0.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.